Table 3.

Comparative multivariable survival analysis the UTUC patients.

Multivariable analysis	OS		DFS		BRFS
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Group
≤ 90 days	1		1		1
> 90 days	1.974 (1.166, 3.343)	0.011*	1.997 (1.137, 3.507)	0.016*	0.848 (0.534, 1.346)	0.484
Sex
Male	1		1		1
Female	0.762 (0.576, 1.009)	0.058	0.886 (0.653, 1.203)	0.438	0.485 (0.395, 0.595)	<0.001**
Age
<70	1		1
≥70	1.662 (1.244, 2.221)	0.001	1.252 (0.940, 1.667)	0.124
ECOG performance status
0	1
1	1.362 (1.003, 1.849)	0.048*	1.244 (0.902, 1.717)	0.184
2	2.969 (1.918, 4.594)	<0.001**	1.589 (0.938, 2.691)	0.085
CCI
0	1
≥1	1.560 (1.038, 2.344)	0.032*
Tumor location
Renal pelvis	1		1
Ureter	1.454 (1.056, 2.002)	0.022*	1.415 (0.994, 2.013)	0.054
Renal pelvis + ureter	1.258 (0.851, 1.859)	0.250	1.514 (1.016, 2.257)	0.041*
Surgical margin
No	1
Yes	3.493 (1.791, 6.811)	<0.001**
Pathological stage T
pTis/pTa/pT1	1		1
pT2	1.443 (1.012, 2.056)	0.043*	2.249 (1.484, 3.410)	<0.001**
pT3	2.173 (1.523, 3.102)	<0.001**	4.430 (2.995, 6.551)	<0.001**
pT4	4.768 (1.859, 12.231)	0.001**	6.240 (2.211, 17.607)	0.001**
Adjuvant systemic therapy
No	1		1
Yes	0.613 (0.394, 0.953)	0.030*	0.497 (0.325, 0.759)	0.001**
Cell Type
UC					1
Not UC					0.724 (0.544, 0.963)	0.026*

Cl, confidence; HR, hazard ratio; OS, overall survival; DFS, disease-free survival; BRFS, Bladder Recurrence-free survival; ECOG, Eastern Cooperative Oncology Group; CCI, Charlson Comorbidity Index

*< 0.05, ** < 0.01